390 related articles for article (PubMed ID: 11236808)
1. The pharmacokinetics of levosalbutamol: what are the clinical implications?
Boulton DW; Fawcett JP
Clin Pharmacokinet; 2001 Jan; 40(1):23-40. PubMed ID: 11236808
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study.
Jantikar A; Brashier B; Maganji M; Raghupathy A; Mahadik P; Gokhale P; Gogtay J; Salvi S
Respir Med; 2007 Apr; 101(4):845-9. PubMed ID: 17276051
[TBL] [Abstract][Full Text] [Related]
3. Enantioselective disposition of salbutamol in man following oral and intravenous administration.
Boulton DW; Fawcett JP
Br J Clin Pharmacol; 1996 Jan; 41(1):35-40. PubMed ID: 8824691
[TBL] [Abstract][Full Text] [Related]
4. Preserved bronchial dilatation after salbutamol does not guarantee protection against bronchial hyperresponsiveness.
Sjöswärd KN; Josefsson M; Ahlner J; Schmekel B
Clin Physiol Funct Imaging; 2003 Jan; 23(1):14-20. PubMed ID: 12558609
[TBL] [Abstract][Full Text] [Related]
5. Levosalbutamol in the treatment of asthma.
Milgrom H
Expert Opin Pharmacother; 2006 Aug; 7(12):1659-68. PubMed ID: 16872269
[TBL] [Abstract][Full Text] [Related]
6. Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man--no evidence of enantioselective lung metabolism.
Ward JK; Dow J; Dallow N; Eynott P; Milleri S; Ventresca GP
Br J Clin Pharmacol; 2000 Jan; 49(1):15-22. PubMed ID: 10606833
[TBL] [Abstract][Full Text] [Related]
7. SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels?
Jacobson GA; Yee KC; Wood-Baker R; Walters EH
Drug Test Anal; 2015 Feb; 7(2):109-13. PubMed ID: 24692077
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers.
Lipworth BJ; Clark DJ; Koch P; Arbeeny C
Thorax; 1997 Oct; 52(10):849-52. PubMed ID: 9404370
[TBL] [Abstract][Full Text] [Related]
9. Beta2-agonist eutomers: a rational option for the treatment of asthma?
Boulton DW; Fawcett JP
Am J Respir Med; 2002; 1(5):305-11. PubMed ID: 14720033
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers.
Schmekel B; Rydberg I; Norlander B; Sjöswärd KN; Ahlner J; Andersson RG
Eur Respir J; 1999 Jun; 13(6):1230-5. PubMed ID: 10445595
[TBL] [Abstract][Full Text] [Related]
11. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol.
Dhand R; Goode M; Reid R; Fink JB; Fahey PJ; Tobin MJ
Am J Respir Crit Care Med; 1999 Oct; 160(4):1136-41. PubMed ID: 10508799
[TBL] [Abstract][Full Text] [Related]
12. Evidence based review on levosalbutamol.
Gupta MK; Singh M
Indian J Pediatr; 2007 Feb; 74(2):161-7. PubMed ID: 17337829
[TBL] [Abstract][Full Text] [Related]
13. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics.
Lima JJ; Thomason DB; Mohamed MH; Eberle LV; Self TH; Johnson JA
Clin Pharmacol Ther; 1999 May; 65(5):519-25. PubMed ID: 10340917
[TBL] [Abstract][Full Text] [Related]
14. Levosalbutamol for chronic obstructive pulmonary disease: a treatment evaluation.
Patel M; Thomson NC
Expert Opin Pharmacother; 2012 May; 13(7):1069-75. PubMed ID: 22364295
[TBL] [Abstract][Full Text] [Related]
15. Levosalbutamol.
Ormrod D; Spencer CM
BioDrugs; 1999 Jun; 11(6):431-8. PubMed ID: 18031154
[TBL] [Abstract][Full Text] [Related]
16. The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists.
Handley D
J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 2):S69-76. PubMed ID: 10452791
[TBL] [Abstract][Full Text] [Related]
17. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.
Bergés R; Segura J; Ventura R; Fitch KD; Morton AR; Farré M; Mas M; de La Torre X
Clin Chem; 2000 Sep; 46(9):1365-75. PubMed ID: 10973867
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of salmeterol.
Cazzola M; Testi R; Matera MG
Clin Pharmacokinet; 2002; 41(1):19-30. PubMed ID: 11825095
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers.
Gumbhir-Shah K; Kellerman DJ; DeGraw S; Koch P; Jusko WJ
J Clin Pharmacol; 1998 Dec; 38(12):1096-106. PubMed ID: 11301561
[TBL] [Abstract][Full Text] [Related]
20. (R)-salbutamol in the treatment of asthma and chronic obstructive airways disease.
Patel M; Thomson NC
Expert Opin Pharmacother; 2011 May; 12(7):1133-41. PubMed ID: 21453221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
